Chapter
Investing in Biomanufacturing facilities post-COVID
44:33 - 52:45 (08:12)
Building biomanufacturing facilities using a few billion dollars from the $1.9 trillion stimulus bill can support the future vaccine and antibody therapeutic supply chain in the US, which is critically needed. However, for-profit companies are relatively risk-averse and may not invest such a large sum.
Clips
The $1.9 trillion stimulus bill will include $350 billion for state and local governments, which is a significant amount that Wall Street has been waiting for.
44:33 - 46:20 (01:46)
Summary
The $1.9 trillion stimulus bill will include $350 billion for state and local governments, which is a significant amount that Wall Street has been waiting for. In comparison, during the financial crisis, Congress passed an $800 billion aid package and last March, an emergency $2 trillion package was passed.
ChapterInvesting in Biomanufacturing facilities post-COVID
EpisodeE18: Inauguration talk, breaking down the $1.9T stimulus, the case for recalling Gavin Newsom & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
The $350 billion package will bridge the financial gap for local level states like Chicago and New York whose revenue has declined, from a lack of tax increase and receipts, during the pandemic.
46:21 - 47:08 (00:47)
Summary
The $350 billion package will bridge the financial gap for local level states like Chicago and New York whose revenue has declined, from a lack of tax increase and receipts, during the pandemic. Municipal bonds have been funding these states, therefore this package will prevent such bonds defaulting and having a ripple effect on the economy, putting many in financial danger.
ChapterInvesting in Biomanufacturing facilities post-COVID
EpisodeE18: Inauguration talk, breaking down the $1.9T stimulus, the case for recalling Gavin Newsom & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
The US is inefficiently investing billions of dollars in COVID-19 fighting measures such as testing and protective gear instead of investing in modular biomanufacturing facilities for future vaccine and antibody therapeutic supply chains, which will be critically needed in the country.
47:08 - 50:08 (03:00)
Summary
The US is inefficiently investing billions of dollars in COVID-19 fighting measures such as testing and protective gear instead of investing in modular biomanufacturing facilities for future vaccine and antibody therapeutic supply chains, which will be critically needed in the country.
ChapterInvesting in Biomanufacturing facilities post-COVID
EpisodeE18: Inauguration talk, breaking down the $1.9T stimulus, the case for recalling Gavin Newsom & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
The US needs to invest more in battery development and infrastructure to compete against Japan and China's dominance in the market, as battery production is crucial to addressing climate change.
50:09 - 52:45 (02:36)
Summary
The US needs to invest more in battery development and infrastructure to compete against Japan and China's dominance in the market, as battery production is crucial to addressing climate change. However, private companies may not be willing to invest the necessary money to build battery infrastructure, and working with other countries and licensing their IP could be a solution.